Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

PF-562271 (besylate)

Catalog No: tcsc2663

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
939791-38-5

Formula:
$C_{27}H_{26}F_3N_7O_6S_2$

Pathway:
Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK

Target:
Pyk2;FAK

Purity / Grade:
>98%

Solubility:
DMSO : 21.4 mg/mL (32.15 mM; Need ultrasonic and warming)

Alternative Names:
PF562271 besylate;PF 562271 besylate

Observed Molecular Weight:
665.66

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

PF-562271 (besylate) is a potent, ATP-competitive, reversible inhibitor of **FAK** and Pyk2 kinase with **IC_{50}** of 1.5 nM and 13 nM, and has > 100-fold selectivity against other protein kinases, except for some CDKs.

IC50 & Target: IC50: 1.5 nM (FAK), 13 nM (Pyk2)

In Vitro: PF-562,271 is a 30- to 120-nM (15.2 to 60.1 ng/mL) inhibitor of cdk2/E, cdk5/p35, cdk1/B, and cdk3/E in recombinant enzyme assays[1]. PF-562,271 blocks bFGF-stimulated blood vessel angiogenesis as performed in chicken chorioallantoic membrane assays[2]. Treatment of cells with PF-562,271 or knock-down of FAK by siRNA is observed to increase cell-cell adhesion strength[3].

In Vivo: PF-562,271 (33 mg/kg, p.o.) inhibits FAK phosphorylation in tumors in a dose- and time-dependent manner in tumor-bearing mice. FAK phosphorylation inhibition relative to total blood concentration of PF-562,271 results in a calculated EC_{50} of 93 ng/mL. PF-562,271 (25 mg/kg, p.o.) induces apoptosis 2-fold greater in treated tumors compared with vehicle-treated control tumors on day 3[1]. PF-562,271 (33 mg/kg, p.o.) and dasatinib extensively inhibit the movement of tumor cells in the animals. Inhibition of FAK kinase activity following treatment with PF-562,271 results in altered E-cadherin dynamics in vivo[3].